anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lmp7-IN-1
Trial phase: Phase 1
SMILES: O=C(NC(Cc1coc2ccccc12)B(O)O)C1CC2CCC1O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
Eligibility criteria:
Inclusion Criteria:

Participants having Eastern Co-operative Oncology Group (ECOG) Performance Status less than or equals to (<=) 1
Adequate hematological, hepatic and renal function as defined in the protocol
Participant must have measurable disease of Multiple Myeloma (MM) and received greater than (>) 3 prior lines of therapy for MM including a Proteasome Inhibitors (PI), an Immunomodulatory Imide Drug (IMiD) and an anti-CD38 mAb or who are refractory to at least PI agent (carfilzomib or bortezomib) and IMiD according to the International Myeloma Working Group (IMWG) criteria
Participant must have documented evidence progressive disease as defined by the IMWG criteria either on or after their last regimen
Other protocol defined inclusion criteria could apply

Exclusion Criteria:

Any condition, including any uncontrolled disease state that in the Investigator's opinion constitutes an inappropriate risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.
An active second malignancy or evidence of disease of cancer (other than MM) before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
Cerebrovascular accident/stroke (< 6 months prior enrollment) or neurologic instability per clinical evaluation due to tumor involvement of the Central Nervous System
Diagnosis of fever within 1 week prior to study intervention administration
Part B: Participants planning to undergo a stem cell transplant should not be enrolled to reduce disease burden prior to transplant.
Other protocol defined exclusion criteria could apply
Intervention: Ferumoxides
Trial phase: Phase 4
SMILES: [Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Ferumoxytol injection: Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
Eligibility criteria:
Inclusion Criteria:

Status post placement of durable ventricular assist device with stable clinical status for >30days
Hemoglobin >6 g/dL AND <13 g/dL (men) or <12 g/dL (women) within last 90 days
Serum ferritin <100 ng/mL OR Serum ferritin 100-299 ng/mL with transferrin saturation <20% within last 90 days
Able and willing to provide written informed consent

Exclusion Criteria:

Known hypersensitivity to Ferumoxytol injection or other intravenous iron preparation
History of anaphylaxis
Treatment with erythropoiesis stimulating agent or intravenous iron in last 3 months
Renal failure on hemodialysis
Respiratory failure on mechanical ventilation
Disabling Stroke
Ventricular assist device thrombosis
Evidence of active gastrointestinal bleeding or other active blood loss
Hospitalization <30 days
Pregnant or breastfeeding women
Intervention: Lasmiditan
Trial phase: Phase 1
ATC code: N02CC08
SMILES: CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants received 50 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 50 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
Eligibility criteria:
Inclusion Criteria:

Are overtly healthy Chinese (all 4 biological grandparents and both biological parents to be of Chinese origin) males or females, as determined by medical history and physical examination
Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter, inclusive
Are able and willing to give signed informed consent

Exclusion Criteria:

Have known allergies to lasmiditan, related compounds or any components of the formulation
Have an abnormal blood pressure and/or pulse rate as determined clinically significant by the investigator
Have a history of, show evidence of, or are undergoing treatment for significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression)
Have a history of central nervous system (CNS) conditions such as strokes, transient ischemic attack, significant head trauma, CNS infections, migraines, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increases the risk of participating in the study
Regularly use known drugs of abuse and/or show positive findings on drug screening
Intervention: Lasmiditan
Trial phase: Phase 1
ATC code: N02CC08
SMILES: CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants received 200 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 200 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
Eligibility criteria:
Inclusion Criteria:

Are overtly healthy Chinese (all 4 biological grandparents and both biological parents to be of Chinese origin) males or females, as determined by medical history and physical examination
Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter, inclusive
Are able and willing to give signed informed consent

Exclusion Criteria:

Have known allergies to lasmiditan, related compounds or any components of the formulation
Have an abnormal blood pressure and/or pulse rate as determined clinically significant by the investigator
Have a history of, show evidence of, or are undergoing treatment for significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression)
Have a history of central nervous system (CNS) conditions such as strokes, transient ischemic attack, significant head trauma, CNS infections, migraines, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increases the risk of participating in the study
Regularly use known drugs of abuse and/or show positive findings on drug screening
Intervention: (2R)-2-amino-3-[1-[3-[3-[2,3-bis(2-methoxyethoxy)propoxy]propylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid
Trial phase: Phase 4
SMILES: COCCOCC(COCCCNC(=O)CCN1C(=O)CC(SCC(N)C(=O)O)C1=O)OCCOC
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Prophylaxis regimens with every 5 days treatment (45-60 IU/kg), or every 7 days (60 IU/kg) or twice per week (40 IU/kg).
Eligibility criteria:
Inclusion Criteria:

Participants must ≥ 18 years of age inclusive, at the time of signing the informed consent.
Participants with severe hemophilia A (FVIII: C<1%)
PTPs (Previously treated patients) (≥150 ED (Exposure day)) on prophylaxis treatment before enrollment
Participants who are immunocompetent. If human immunodeficiency virus (HIV) positive, cluster of differentiation 4 (CD4)+ lymphocyte count >200/mm*3
Participants who are willing to complete an eDiary
Male participants
Capable of giving signed informed consent

Exclusion Criteria:

Any other inherited or acquired bleeding disorder in addition to Hemophilia A.
Platelet count < 100,000/mm*3
Creatinine > 2x upper limit of normal
AST or ALT > 5x upper limit of normal (AST: aspartate aminotransferase; ALT: alanine aminotransferase)
The participant has a planned major surgery.
The participant is currently participating in another investigational drug study, or has participated in a clinical study involving an investigational drug within 30 days of signing informed consent or previous treatment in a clinical phase III study with BAY 94-9027 (now marketed as Jivi).
Current evidence (by central laboratory) or history of inhibitor to FVIII with a titer ≥ 0.6 Bethesda unit (BU).
Known hypersensitivity to the drug substance, excipients, or mouse or hamster protein.
Intervention: Oxybutynin
Trial phase: Phase 4
ATC code: G04BD04
SMILES: CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Women presenting to the Urogynecology clinic with urgency urinary incontinence symptoms will receive standard of care anticholinergic treatment and will have their urinary microbiome evaluated before and after treatment

Oxybutynin, Solifenacin, Tolterodine, Sanctura or Toviaz: Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
Eligibility criteria:
Inclusion Criteria:

Postmenopausal (Age ≥ 50) women with Urgency Urinary Incontinence (UUI)
English speaking
Willing to take anticholinergics for at least 6 weeks
Willing to complete UDI-6 and voiding diary at baseline and 6 weeks
Willing to give urine and blood for study at baseline and 6 weeks

Exclusion Criteria:

Have taken anticholinergic medication within the last month
Have taken antibiotics within the last month
Urinary Tract Infection (UTI) in the last three months
Neurological disease (eg. Parkinson's disease, Multiple Sclerosis, etc.)
Immunological deficiencies
History of sexually transmitted disease (STD)
Lack of consent
Not ambulatory (e.g. uses a wheelchair)
Intervention: PROPYLENE GLYCOL
Trial phase: Phase 4
SMILES: CC(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Tear evaporation was measured prior to and after Systane Complete was instilled in a group of people without dry eye that had an Ocular Surface Disease Index score <13 and a non-invasive Keratograph break-up time >/= 10 seconds in the worst eye.
Eligibility criteria:
Inclusion Criteria:

Is at least 18 years of age and has full legal capacity to volunteer;
Has read and signed an information consent letter;
Is willing and able to follow instructions and maintain the appointment schedule;
Is willing to be awake for at least 2 hours before visit 2;
Is willing not to wear eye makeup on the day of visit 2;
Is willing not to use eye drops or artificial tears on the days of visits 1 or 2;

Group specific criteria:

Dry eye participant group: Symptoms: OSDI ≥ 13 and Signs: NIKBUT ≤ 5 s in the worst eye
Non-dry eye participant group: Symptoms: OSDI < 13 and Signs: NIKBUT ≥ 10 s in the worst eye

Exclusion Criteria:

Is participating in any concurrent clinical or research study;
Has any known active* ocular disease and/or infection;
Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
Has known sensitivity to sodium fluorescein dye;
Is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit);
Is aphakic;
Has undergone refractive error surgery;
Has undergone ocular surgery in the last 6 months;
Has punctal plugs;
Has a known sensitivity to Systane eye drops (including Systane Balance, Systane Complete, Systane Gel Drops, Systane Ultra, etc.)
Has a known sensitivity to petroleum jelly (Vaseline);
Has epilepsy and/or sensitivity to flashing lights;
Has worn contact lenses within the past month or is planning to wear contact lenses during the study;
Has any physical impairment that would interfere with holding the evaporimeter;
Has taken part in another clinical research study involving ocular drops or treatments within the last 14 days; * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Intervention: PROPYLENE GLYCOL
Trial phase: Phase 4
SMILES: CC(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Tear evaporation was measured prior to and after Systane Complete was instilled in a group of people with dry eye that had an Ocular Surface Disease Index score >/=13 and a non-invasive Keratograph break-up time </= 5 seconds in the worst eye.
Eligibility criteria:
Inclusion Criteria:

Is at least 18 years of age and has full legal capacity to volunteer;
Has read and signed an information consent letter;
Is willing and able to follow instructions and maintain the appointment schedule;
Is willing to be awake for at least 2 hours before visit 2;
Is willing not to wear eye makeup on the day of visit 2;
Is willing not to use eye drops or artificial tears on the days of visits 1 or 2;

Group specific criteria:

Dry eye participant group: Symptoms: OSDI ≥ 13 and Signs: NIKBUT ≤ 5 s in the worst eye
Non-dry eye participant group: Symptoms: OSDI < 13 and Signs: NIKBUT ≥ 10 s in the worst eye

Exclusion Criteria:

Is participating in any concurrent clinical or research study;
Has any known active* ocular disease and/or infection;
Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
Has known sensitivity to sodium fluorescein dye;
Is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit);
Is aphakic;
Has undergone refractive error surgery;
Has undergone ocular surgery in the last 6 months;
Has punctal plugs;
Has a known sensitivity to Systane eye drops (including Systane Balance, Systane Complete, Systane Gel Drops, Systane Ultra, etc.)
Has a known sensitivity to petroleum jelly (Vaseline);
Has epilepsy and/or sensitivity to flashing lights;
Has worn contact lenses within the past month or is planning to wear contact lenses during the study;
Has any physical impairment that would interfere with holding the evaporimeter;
Has taken part in another clinical research study involving ocular drops or treatments within the last 14 days; * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Intervention: CID 163285897
Trial phase: Phase 3
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 230
Group description: Participants received 5 mg tirzepatide administered SC QW.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months
Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use [≤14 consecutive days] for acute conditions)
HbA1c ≥7.5% to ≤11.0% at screening
Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment
Body mass Index (BMI) ≥23 kilograms per meter squared

Exclusion Criteria:

Type 1 diabetes mellitus
Have history of chronic or acute pancreatitis
Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
Have a history of ketoacidosis or hyperosmolar state/coma
Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility
Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months
Intervention: CID 163285897
Trial phase: Phase 3
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 228
Group description: Participants received 10 mg tirzepatide administered SC QW.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months
Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use [≤14 consecutive days] for acute conditions)
HbA1c ≥7.5% to ≤11.0% at screening
Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment
Body mass Index (BMI) ≥23 kilograms per meter squared

Exclusion Criteria:

Type 1 diabetes mellitus
Have history of chronic or acute pancreatitis
Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
Have a history of ketoacidosis or hyperosmolar state/coma
Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility
Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months
Intervention: CID 163285897
Trial phase: Phase 3
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 229
Group description: Participants received 15 mg tirzepatide administered SC QW.
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes mellitus
Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months
Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use [≤14 consecutive days] for acute conditions)
HbA1c ≥7.5% to ≤11.0% at screening
Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment
Body mass Index (BMI) ≥23 kilograms per meter squared

Exclusion Criteria:

Type 1 diabetes mellitus
Have history of chronic or acute pancreatitis
Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
Have a history of ketoacidosis or hyperosmolar state/coma
Have a known clinically significant gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility
Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months